Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-infectious Uveitis Clear all
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

NCT01789320
View directory record Official record
Conditions
Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Noninfectious Uveitis
Interventions
triamcinolone acetonide (Triesence®)
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • Omaha, Nebraska • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 8, 2026, 11:02 AM EDT
Terminated Phase 2Phase 3 Interventional

A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis

NCT00333996
View directory record Official record
Conditions
Anterior Uveitis
Interventions
Dexamethasone
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 3 Interventional

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

NCT00404742
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions
Placebo, LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
13 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Sep 8, 2026, 11:02 AM EDT
Withdrawn Phase 2 Interventional

Intravitreal Sirolimus as Therapeutic Approach to Uveitis

NCT01280669
View directory record Official record
Conditions
Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
Interventions
Intravitreal injection 440mcg, Intravitreal injection of sirolimus 880mcg
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 8, 2026, 11:02 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

NCT01717170
View directory record Official record
Conditions
Intermediate Uveitis, Posterior Uveitis, Pan-uveitis
Interventions
Tocilizumab
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 100 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 8, 2026, 11:02 AM EDT
Recruiting Phase 2 Interventional

Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis

NCT07285070
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
Tacrolimus ophthalmic solution
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
6
States / cities
Phoenix, Arizona • Miami, Florida • Waltham, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis

NCT02595398
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4mg CLS-TA Suprachoriodal Injection, Sham Procedure
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Results available

Sirolimus as Therapeutic Approach to Uveitis

NCT00908466
View directory record Official record
Conditions
Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
Interventions
Sirolimus (rapamycin)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

NCT00525902
View directory record Official record
Conditions
Uveitis
Interventions
Adalimumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Sep 8, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional

Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

NCT05384249
View directory record Official record
Conditions
Uveitis
Interventions
Izokibep, Placebo
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
36
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 8, 2026, 11:02 AM EDT
Not listed Phase 4 Interventional

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

NCT05322070
View directory record Official record
Conditions
Uveitis, Posterior
Interventions
Fluocinolone Acetonide Intravitreal Implant 0.18 mg
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Fullerton, California • Glendale, California • Pasadena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

NCT02517619
View directory record Official record
Conditions
Anterior Uveitis
Interventions
Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%)
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 8, 2026, 11:02 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01032915
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Artesia, California • Beverly Hills, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis

NCT04222712
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
TRS01 eye drops
Drug
Lead sponsor
Tarsier Pharma
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Palisades Park, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

NCT01694186
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI insert, Sham injection
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
16
States / cities
Beverly Hills, California • Sacramento, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 8, 2026, 11:02 AM EDT
Terminated Phase 3 Interventional Results available

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

NCT03711929
View directory record Official record
Conditions
Non Infectious Uveitis
Interventions
DE-109 Intravitreal Injections, Sham Procedure, DE-109 Intravitreal Injections (Open Label)
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 2 Interventional

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

NCT05523765
View directory record Official record
Conditions
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis
Interventions
Brepocitinib
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Sep 8, 2026, 11:02 AM EDT
Completed No phase listed Observational Results available

MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301

NCT02952001
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4 mg CLS-TA Suprachoriodal Injection, Sham procedure
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Mountain View, California • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Not applicable Interventional Results available

Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema

NCT00790803
View directory record Official record
Conditions
Uveitis, Cystoid Macular Edema
Interventions
Pegaptanib
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 8, 2026, 11:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate

NCT01314417
View directory record Official record
Conditions
Non-infectious Intermediate and Posterior Uveitis
Interventions
Methotrexate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Results available

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697
View directory record Official record
Conditions
Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
Drug
Lead sponsor
Tampa Bay Uveitis Center, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 8, 2026, 11:02 AM EDT
Not listed Phase 4 Interventional

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

NCT03066869
View directory record Official record
Conditions
Uveitis, Posterior, Vasculitis Retinal
Interventions
H.P. ACTHAR GEL
Drug
Lead sponsor
Ocular Immunology and Uveitis Foundation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 2 Interventional

ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)

NCT02931175
View directory record Official record
Conditions
Uveitis
Interventions
ACTH gel
Drug
Lead sponsor
Quan Dong Nguyen
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Waltham, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis

NCT02309385
View directory record Official record
Conditions
Non-Infectious Anterior Uveitis
Interventions
8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops
Drug
Lead sponsor
Aciont Inc
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Cambridge, Massachusetts • Charlotte, North Carolina • Fargo, North Dakota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 8, 2026, 11:02 AM EDT